Literature DB >> 26165199

Hormone Therapy for Breast Cancer in Men.

Muhammad Habibullah Khan1, Rozenn Allerton2, Laura Pettit3.   

Abstract

Breast cancer in men is rare, but its incidence is increasing, in keeping with the aging population. The majority of breast cancers in men are estrogen receptor positive. There is a paucity of clinical trials to inform practice, and much has been extrapolated from breast cancer in women. Hormone therapy represents the mainstay of adjuvant and palliative therapy but may have contraindications or poor tolerability. We review the evidence for choice of hormone therapy in both the adjuvant and palliative setting in breast cancer in men.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Hormone therapy; Male

Mesh:

Substances:

Year:  2015        PMID: 26165199     DOI: 10.1016/j.clbc.2015.01.007

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  10 in total

1.  Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes.

Authors:  Francesco Giotta; Luigi Acito; Giampiero Candeloro; Pietro Del Medico; Gennaro Gadaleta-Caldarola; Guido Giordano; Rossana Gueli; Antonio Lugini; Valentina Magri; Marta Mandarà; Giovanna Masci; Salvatore Pisconti; Mirco Pistelli; Anna Rizzi; Nello Salesi; Alessio Schirone; Giovanni Scognamiglio; Maria Tedeschi; Patrizia Zucchinelli
Journal:  Oncologist       Date:  2016-10-14

Review 2.  Environmental endocrine disruptors: Effects on the human male reproductive system.

Authors:  M F Sweeney; N Hasan; A M Soto; C Sonnenschein
Journal:  Rev Endocr Metab Disord       Date:  2015-12       Impact factor: 6.514

3.  Male occult triple-negative breast cancer with dermatomyositis: a case report and review of the literature.

Authors:  Le Zhang; Chenghua Zhang; Zhaoying Yang; Miao He; Lijuan Zhang; Shereen Ezzat; Xi Liang
Journal:  Onco Targets Ther       Date:  2017-11-14       Impact factor: 4.147

4.  Intracystic papillary carcinoma of the male breast: a case report.

Authors:  Haruhito Kinoshita; Shinichiro Kashiwagi; Hitoshi Teraoka; Takuya Mori; Kenji Kuroda; Mikio Nanbara; Eiji Noda; Takaaki Chikugo; Kosei Hirakawa; Masaichi Ohira
Journal:  World J Surg Oncol       Date:  2018-01-23       Impact factor: 2.754

5.  Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer - a SEER analysis.

Authors:  Nikita Abhyankar; Kent F Hoskins; Michael R Abern; Gregory S Calip
Journal:  BMC Cancer       Date:  2017-09-25       Impact factor: 4.430

6.  Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers.

Authors:  Piera Rizzolo; Anna Sara Navazio; Valentina Silvestri; Virginia Valentini; Veronica Zelli; Ines Zanna; Giovanna Masala; Simonetta Bianchi; Marco Scarnò; Stefania Tommasi; Domenico Palli; Laura Ottini
Journal:  Oncotarget       Date:  2016-11-08

7.  Diagnosis, Prognosis, and Management of Breast Cancer in an 81-Year-Old Male Patient.

Authors:  Jimmy George; Audrey Albach; Angelica S Robinson; Linden Dixon; Quan D Nguyen
Journal:  Cureus       Date:  2020-05-25

Review 8.  Oncotype DX for Comprehensive Treatment in Male Breast Cancer: A Case Report and Literature Review.

Authors:  Ang Zheng; Lin Zhang; Ziyao Ji; Lijuan Fan; Feng Jin
Journal:  Am J Mens Health       Date:  2019 May-Jun

Review 9.  Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer.

Authors:  Dylan P McClurg; Gordan Urquhart; Trevor McGoldrick; Subarnarekha Chatterji; Zosia Miedzybrodzka; Valerie Speirs; Beatrix Elsberger
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

Review 10.  Management of Male Breast Cancer: The Journey so Far and Future Directions.

Authors:  Quratulain Anna Sabih; Jessica Young; Kazuaki Takabe
Journal:  World J Oncol       Date:  2021-12-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.